Market Overview

ACADIA Pharma Shares Move Higher as JMP Boosted Price Target from $16 to $27

Share:
Related ACAD
Why Are Analysts So Bullish On This Tumbling Biotech Company?
Benzinga's Top Initiations

JMP Securities maintains ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) with a Market Outperform and raises the price target from $16.00 to $27.00.

The stock has opened up more than 4 percent higher. With the stock last trading at $19.45, the firm's new price target implies potential upside of about 39 percent.

Latest Ratings for ACAD

DateFirmActionFromTo
Feb 2016Bank of AmericaInitiates Coverage onBuy
Jan 2016Piper JaffrayUpgradesNeutralOverweight
Nov 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for ACAD
View the Latest Analyst Ratings

Posted-In: News Price Target Analyst Ratings

 

Related Articles (ACAD)

Get Benzinga's Newsletters